Why the study?
Does late gadolinium enhancement on CMR predict the composite of death, non-sustained VT, or VF in pediatric patients with hypertrophic cardiomyopathy?
Does late gadolinium enhancement on CMR predict the composite of death, non-sustained VT, or VF in pediatric patients with hypertrophic cardiomyopathy?
LGE on CMR may identify higher-risk pediatric HCM patients; hypothesis-generating for risk stratification, needs prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: